Micrococcus luteus Extracellular Vesicles for Neuroinflammation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurodevelopmental, neurologic, and psychiatric diseases are inadequate in addressing the underlying immune and metabolic dysfunctions, particularly the abnormal death of neural stem cells and inter-neuronal integrity issues associated with chronic inflammation and neurodegeneration.
Innovation Solution
The use of extracellular vesicles derived from Micrococcus luteus, which inhibit inflammatory mediator secretion, regulate immune functions by suppressing NLRP3 protein expression, enhance endothelial NO synthase activity, and promote neurogenesis by activating brain-derived neurotrophic factor and sirtuin proteins.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for neurodevelopmental, neurologic, and psychiatric diseases, then current standard therapies can be administered, but they fail to address the underlying immune and metabolic dysfunctions causing abnormal cell death and neurodegeneration
Solution Approach 1:
The patent uses extracellular vesicles from Micrococcus luteus as intermediary substances that mediate between the gut microbiome and the nervous system. These vesicles carry beneficial molecules that can cross the blood-brain barrier and address underlying immune and metabolic dysfunctions, rather than merely suppressing symptoms. The vesicles act as a bridge to restore homeostasis in neural stem cells and reduce neurodegeneration.
Solution Approach 2:
The patent changes the therapeutic approach by modifying the biochemical parameters of the treatment target. Instead of using conventional drugs that act on neural pathways, the invention uses extracellular vesicles that alter immune and metabolic parameters at their source. This includes changing the expression of NLRP3 protein, regulating inflammatory mediators, and restoring metabolic functions in neural stem cells, thereby addressing the root causes rather than just treating symptoms.
2Ease of operation
If treatments focus on symptom management, then quality of life may be maintained, but the underlying causes including abnormal death of neural stem cells and inter-neuronal integrity issues remain unaddressed
Solution Approach 1:
The patent applies preliminary action by addressing the underlying causes before they lead to irreversible neurodegeneration. The extracellular vesicles from Micrococcus luteus prevent abnormal cell death of neural stem cells and maintain inter-neuronal integrity by regulating immune functions and metabolic pathways. This preventive approach stops the disease progression at its source rather than managing symptoms after damage has occurred.
Solution Approach 2:
The patent converts the harmful effects of chronic inflammation and immune dysfunction into beneficial outcomes. By using extracellular vesicles that regulate NLRP3 protein expression and inflammatory mediator secretion, the treatment transforms the harmful inflammatory response into a protective mechanism. The same immune system that causes neurodegeneration is redirected to protect and regenerate neural stem cells.
3Reliability
If extracellular vesicles from Micrococcus luteus are used, then immune functions are regulated and neurogenesis is promoted, but the mechanism involves complex interactions with NLRP3 protein and inflammatory mediators
Solution Approach 1:
The patent segments the complex mechanism into distinct functional components: (1) regulation of NLRP3 protein expression, (2) control of inflammatory mediator secretion, (3) activation of endothelial NO synthase, and (4) promotion of neurogenesis through BDNF and sirtuin proteins. This segmentation allows the complex immune-neuro interaction to be understood and treated as separate manageable processes, each addressed by specific molecular targets within the extracellular vesicles.
Data Source
AI summary
Provided is a method for alleviating, preventing or treating a neurodevelopmental disease, neurologic disease, or psychiatric disease, comprising administering to a subject in need thereof a composition including, as an active ingredient, vesicle derived from Micrococcus luteus, wherein the disease including Alzheimer's disease, Parkinson's disease, amyotropic lateral sclerosis, Huntington's disease, epilepsy, multiple sclerosis, chronic inflammatory demyelinating polyneuropathy, diabetic neuropathy, autism spectrum disorder, attention deficit hyperactivity syndrome, major depressive disorder, bipolar disorder, anxiety disorders, schizophrenia, obsessive compulsive disorder, post-traumatic stress disorder, dissociative disorders, eating disorders, substance use disorder, and personality disorders occurring as a result of neurogenesis dysfunction or neuroinflammation.